WebsEdge/Health

Traditionally the bulk of radiology and nuclear medicine practices have focused on diagnostics. The advent of multiple emerging agents in the theragnostic spectrum are changing practice focus to allow not only targeted diagnosis of disease, but also paired focused therapy. OSUWMC has been an early leader in this exciting frontier, starting to offer Ga-68 Dotatate PET/CT in 2016 to clinical patients for a targeted approach to staging and restaging of Neuroendocrine malignancies shortly after FDA approval. The first to offer this diagnostic tool in the region, OSU has continued to be a leading center in number of patients staged, with over 450 completed to date. With the recent availability of Lu-177 Dotatate, starting in late 2017, OSU was the first and only institution in the region to offer a theragnostic program for late stage patients suffering from well-differentiated neuroendocrine tumors. By engaging on the forefront of this clinical service, OSU developed a multi-disciplinary, team-based approach, incorporating leaders from Oncology, Nursing, Radiology, Pharmacy, and Radiation Safety to offer a well-coordinated, efficient, and unique opportunity to patients who previously had very few options.